Gestational trophoblastic neoplasia differential diagnosis

	Gestational trophoblastic neoplasia Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Gestational trophoblastic neoplasia from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Gestational trophoblastic neoplasia differential diagnosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Gestational trophoblastic neoplasia differential diagnosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Gestational trophoblastic neoplasia differential diagnosis
CDC on Gestational trophoblastic neoplasia differential diagnosis
Gestational trophoblastic neoplasia differential diagnosis in the news
Blogs on Gestational trophoblastic neoplasia differential diagnosis
Directions to Hospitals Treating Gestational trophoblastic neoplasia
Risk calculators and risk factors for Gestational trophoblastic neoplasia differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Monalisa Dmello, M.B,B.S., M.D. [2]

Overview

Choriocarcinoma must be differentiated from non neoplastic diseases, neoplastic diseases, and other causes of bleeding during pregnancy.

Choriocarcinoma must be differentiated from other non-neoplastic diseases such as:

Choriocarcinoma must be differentiated from other neoplastic diseases such as:

Choriocarcinoma must be differentiated from other causes of bleeding during pregnancy:


Differential Diagnosis	Clinical Features					Karyotype	Immunostaining							Management
Differential Diagnosis	Presenting Complaints	Potential for Neoplastic Conversion	Beta Human Chorionic Gonadotropin (Beta-hCG) Baseline Levels	History of Pregnancy	Metastatic Route	Karyotype	Cytokeratin 18	HLA-G	Human Chorionic Gonadotropin (hCG)	Transformation-Related Protein 63 (P63)	Human Placental Lactogen (hPL)	Melanoma Cell Adhesion Molecule (Mel-CAM)	Ki67	Management


Clinical Features	Complete Hydatidiform Mole	Partial Hydatidiform Mole	Invasive Molar Pregnancy	Choriocarcinoma	Placental-site trophoblastic tumor (PSTT) and Epithelioid trophoblastic tumor (ETT)
Presenting Complaints	Vaginal bleeding Inappropriately large for date uterine size Hyperemesis	Vaginal bleeding	Vaginal bleeding Elevated beta-hCG	Vaginal bleeding	Vaginal bleeding
Neoplastic Conversion	High rate of progression (15-20%)	< 5 % progression rate	Neoplastic	Neoplastic	Neoplastic
Beta Human Chorionic Gonadotropin (Beta-hCG) baseline levels	Extremely high levels ( > 100000 mIU/ml in half of the patients	Highly elevated ( > 100000 mIU/ml in one in ten patients)	High	High	Moderatley elevated (< 1000 mIU/ml in majority of patients)
History of Pregnancies	Not related	Not related	Consequence of molar pregnancy	Approximately half of the cases occur as a consequence of molar pregnancy Quarter of the cases follow abortion or tubal pregnancy Rest follow term or pre-term pregnancy	About 60% follow term pregnancy 40 % follow molar pregnancy or abortion
Metastatic Route	Benign	Benign	Hematogenous	Hematogenous	Lymphatic
Management	Dilation and curettage (suction)	Dilation and curettage (suction)	Chemotherapy (Methotrexate)	Chemotherapy (Methotrexate)	Hysterectomy